Literature DB >> 8927668

Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).

L Ravizza1, G Barzega, S Bellino, F Bogetto, G Maina.   

Abstract

A 2-year, open-label followup was performed on 130 obsessive-compulsive patients who were responders to a previous 6-month treatment with clomipramine (150 mg/day), fluoxetine (40 mg/day), or fluvoxamine (300 mg/day). Continuation treatment with the same daily dose was compared to continuation with half doses or to discontinuation of pharmacotherapy. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and the Clinical Global Impressions (CGI) scale were used every 3 months, or whenever a worsening of symptoms was experienced. Maintenance treatments were found significantly superior to discontinuation in preventing relapses, and no differences in efficacy were found between full and half doses. A comparison of the three subgroups of patients who were withdrawn from drug therapy failed to demonstrate any statistical difference.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8927668

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  15 in total

1.  Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods.

Authors:  Christina L Boisseau; Steven A Rasmussen
Journal:  Contemp Clin Trials       Date:  2018-01-03       Impact factor: 2.226

2.  Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up.

Authors:  Andreas Kordon; Kai G Kahl; Andreas Broocks; Ulrich Voderholzer; Hildegard Rasche-Räuchle; Fritz Hohagen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 3.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Authors:  D P Figgitt; K J McClellan
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

4.  The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake.

Authors:  Anthony Pinto; Maria C Mancebo; Jane L Eisen; Maria E Pagano; Steve A Rasmussen
Journal:  J Clin Psychiatry       Date:  2006-05       Impact factor: 4.384

Review 5.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

6.  Current management of obsessive and phobic states.

Authors:  Serena Goljevscek; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-30       Impact factor: 2.570

Review 7.  Drug treatment of obsessive-compulsive disorder.

Authors:  Michael Kellner
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

8.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

9.  Obsessive-compulsive disorder and related disorders: a comprehensive survey.

Authors:  Michele Fornaro; Filippo Gabrielli; Claudio Albano; Stefania Fornaro; Salvatore Rizzato; Chiara Mattei; Paola Solano; Valentina Vinciguerra; Pantaleo Fornaro
Journal:  Ann Gen Psychiatry       Date:  2009-05-18       Impact factor: 3.455

10.  Management of obsessive-compulsive disorder with fluvoxamine extended release.

Authors:  Lídia Ordacgi; Mauro V Mendlowicz; Leonardo F Fontenelle
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.